在瘤学中估计受限制的平均响应时间 (RMDoR)
Antonios Daletzakis1,2, Kit C B Roes2, Marianne A Jonker2
1Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pharmaceutical statistics
|February 7, 2025
概括
受限制的平均响应持续时间 (RMDoR) 是对治疗有效性的有用指标,特别是在处理被审查的数据时. 本研究探讨了临床试验中间隔审查数据的RMDoR估计方法.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 卫生经济学 卫生经济学
背景情况:
- 响应持续时间 (DoR) 是临床试验中一个关键的疗效终点.
- 估计DoR是具有挑战性的,因为正确审查的患者随访时间.
- 限制反应平均持续时间 (RMDoR) 是一种替代估计,在实践中经常使用.
研究的目的:
- 为了评估RMDoR的行为作为时间的函数.
- 评估RMDoR对于量化治疗疗效的适用性.
- 开发和比较RMDoR与间隔审查数据的估计器.
主要方法:
- 该研究将RMDoR视为特定时间间隔的函数.
- 建议多个统计估计器处理间隔审查数据.
- 这些估计器的性能在单臂和随机对照试验设置中进行评估.
主要成果:
- 分析了RMDoR作为时间函数的行为.
- 该研究为RMDoR计算间隔审查提供了新的估计器.
- 对估计器的绩效评估提供了对其可靠性的见解.
结论:
- RMDoR是治疗疗效的有价值指标,特别是在难以直接估计DoR的情况下.
- 拟议的估计器为在瘤学试验中分析间隔审查数据提供了强大的方法.
- 这项工作有助于改善临床试验分析中的统计实践.
相关概念视频
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


